Related Experiment Video

Updated: Mar 5, 2026

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines
08:01

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines

Published on: April 21, 2022

2.3K

Targeting BAP1: a new paradigm for mesothelioma

L M Schunselaar1, W Zwart1, P Baas2

  • 1Division of Molecular Pathology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.

Lung Cancer (Amsterdam, Netherlands)
|March 27, 2017
PubMed

Insights

Targeting BAP1 mutations in malignant pleural mesothelioma (MPM) offers new therapeutic avenues. Preclinical studies show promise for inhibitors, but further research is needed to fully understand BAP1

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Malignant pleural mesothelioma (MPM) requires novel treatment strategies.
  • BAP1 mutations are frequently observed in MPM tumors (47-67%), presenting a viable therapeutic target.

Discussion:

  • The diverse functions of BAP1 lead to varied phenotypic effects in MPM.
  • Preclinical data suggests that inhibitors targeting BAP1's phenotypic effects are promising.

Key Insights:

  • BAP1 is a significant driver in MPM pathogenesis.
  • Inhibitors targeting BAP1-associated phenotypes show potential for MPM treatment.

Outlook:

  • Further research into the precise mechanisms of BAP1 is crucial.
  • Elucidating BAP1's role will facilitate the development of more effective targeted therapies and novel inhibitors for MPM.
Keywords:
BAP1InhibitorLossMalignant mesotheliomaMutationTargeting

More Related Videos

In Vitro Ubiquitination and Deubiquitination Assays of Nucleosomal Histones11:36

In Vitro Ubiquitination and Deubiquitination Assays of Nucleosomal Histones

Published on: July 25, 2019

11.6K
Desthiobiotin-Streptavidin-Affinity Mediated Purification of RNA-Interacting Proteins in Mesothelioma Cells11:11

Desthiobiotin-Streptavidin-Affinity Mediated Purification of RNA-Interacting Proteins in Mesothelioma Cells

Published on: April 25, 2018

8.7K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
9.0K